Table 4.

Relationship between use of postmenopausal hormone therapy and risk of different histologic types of breast cancer

HT useControls (n = 2,029)Ductal (n = 1,424)
Lobular (n = 146)
Ductal-lobular (n = 109)
Medullary (n = 26)
Tubular (n = 36)
Comedo (n = 22)
Mucinous (n = 30)
nnOR (95% CI)nOR (95% CI)nOR (95% CI)nOR (95% CI)nOR (95% CI)nOR (95% CI)nOR (95% CI)
Never7315531.0 (ref)551.0 (ref)281.0 (ref)151.0 (ref)101.0 (ref)41.0 (ref)111.0 (ref)
Former2081140.7 (0.5-0.9)*141.0 (0.5-1.8)60.7 (0.3-1.8)20.6 (0.1-2.6)10.3 (0.1-2.6)44.4 (1.1-17.9)*10.3 (0.0-2.5)
Current E5433150.7 (0.6-0.9)*351.0 (0.6-1.5)281.3 (0.7-2.3)40.5 (0.2-1.6)40.5 (0.1-1.6)84.1 (1.2-14.5)*80.8 (0.3-2.2)
Current E + P3653471.2 (1.0-1.5)421.5 (1.0-2.4)472.9 (1.7-4.9)*30.8 (0.2-3.0)203.2 (1.3-7.5)*33.0 (0.6-14.7)91.3 (0.5-3.3)
Phomogeneity = 0.0004
  • NOTE: All ORs are adjusted for age, race, and study site.

    Abbreviations: E, unopposed estrogen hormone therapy; E + P, combined estrogen and progestin hormone therapy.

  • * P < 0.05.

  • Pheterogeneity in the ORs across the six different histologic types of breast cancer.